CS Paper Radar

ARO: Aligned Representation learning for multi-Omics data

Amogh Singh, Yash Shah, Chiara D'Ercoli, Arash Mehrjou, Patrick Schwab, Timothy Jones, Pietro Liò

cs.LG cs.AI ·submitted 2026-10-05 14:49 UTC · v1
published

Abstract

The high cost of functional molecular assays, and prevalence of missing modalities and unmatched samples in computational biology, create significant barriers to comprehensive multi-omic profiling, essential for capturing and reasoning over molecules, cells, tissues, and organisms. This work proposes a model that learns meaningful representations from multi-omics cancer data supporting the reconstruction of missing and unpaired modalities. Contrary to increasingly complex, larger models, e.g. Foundation Models (FMs), ARO prioritizes practical applicability in limited or incomplete data settings. ARO optimally reconstructs missing modalities (MSE of $0.15$ on the validation and test data in the Unmasked settings), with its learned latent embeddings enabling a downstream cancer classification task. Our findings indicate that analyzing diverse molecular layers as a single integrated system offers a reliable and cost-efficient approach, reducing dependence on large-scale experimental testing, while still supporting multi-omic exploration in limited data settings.

Comment
Proceedings of the ICML 2026 3rd Workshop on Multi-modal Foundation Models and Large Language Models for Life Sciences, Seoul, Korea

Closest papers

Nearest neighbours by meaning across the whole index.

Synthesis of Ovarian Cancer Multi-Omics Datasets: A Biology-Informed Evaluation Framework

cs.LG ·2026-11-05 ·Déborah Boyenval, Alina Malyutina, Jaana Oikkonen, Sammeli Liikkanen, Sampsa Hautaniemi
published similarity 0.69
Abstract · Accepted at the GenAI4Health Workshop at NeurIPS 2026 and in the Findings track of ML4H 2026. Both acceptances are non-archival

Paired multi-omic cancer cohorts are costly to assemble and difficult to share, motivating synthetic cohorts as a complementary resource. As generative model development accelerates, we shift the focus from proposing yet another architecture to defining evaluation criteria that determine whether synthetic data preserve biologically relevant structure. We introduce a biology-informed and patient-disjoint framework for evaluating the generation of paired RNA expression and copy-number variation (CNV) profiles, and apply it to the longitudinal DECIDER high-grade serous ovarian cancer cohort. The framework assesses modality-specific fidelity and coherence between RNA and CNV pairs using agreement between real training and held-out data as a reference, alongside complementary training-data proximity diagnostics. We adapt three multi-omic integration architectures based on variational autoencoders to generate paired profiles. The model leading several fidelity and coherence measures also shows the strongest training-data proximity. The protocol and case study offer the community a reference for comparing future multi-omic generators.

0.22

ILR-SMO: Iterative Latent Refinement for Robust Spatial Multi-Omics Integration

cs.LG ·2026-11-02 ·Anqi Yu, Xudong Xu, Jianzhi Lu, Yuqi Sun, Bingguo Chen +3 more
top venue similarity 0.68
Abstract · Author-corrected version of the IJCAI-ECAI 2026 paper. Four numerical typographical errors in Table 1 have been corrected, and the caption h…

Spatial multi-omics technologies jointly profile diverse molecular modalities with spatial context, providing a comprehensive view of cellular heterogeneity and tissue organization. To integrate spatial multi-omics data and identify spatial domains, a wide range of unsupervised methods has been proposed. However, recent approaches rely on single-step fusion, directly aggregating heterogeneous modalities into a shared representation, making embeddings sensitive to modality imbalance and measurement noise that are inherent to spatial multi-omics data, as well as unstable optimization under weak supervision. Here, we propose ILR-SMO (Iterative Latent Refinement for Spatial Multi-Omics), a unified self-supervised framework that reformulates multimodal integration as a stability-aware refinement process over a shared latent representation. Instead of single-step plain fusion, ILR-SMO progressively integrates modality-specific information through sequential updates, allowing information to be injected in a controlled manner. This incremental refinement enables later updates to correct or compensate for earlier deviations, resulting in more stable and robust representation learning under heterogeneous and noisy modalities. ILR-SMO further incorporates reliability-aware modality gating for adaptive modulation of modality contributions, and employs a joint objective to enforce spatial coherence while preventing representation collapse. Extensive experiments on five spatial multi-omics benchmarks demonstrate that ILR-SMO consistently outperforms seven state-of-the-art methods and exhibits strong robustness across diverse settings.

0.42

Real-World Multi-Modal and Longitudinal Lung Cancer Dataset

eess.IV cs.CV ·2026-09-04 ·Rita Cordeiro Mendes, Maria Rita Fonseca Verdelho, Carlos Santiago, Catarina Barata
publishedbenchmarkcode/data similarity 0.67
Abstract · Accepted at ECCV 2026 Workshop on Data Curation & Augmentation in Medical Imaging

Multi-modal learning has demonstrated strong potential in medical applications by integrating heterogeneous data sources such as medical imaging, clinical records, and genomics to improve predictive performance and support clinical decision-making. However, advances in this area are often constrained by two key challenges: the limited availability of well-curated, ready-to-use datasets that accurately reflect real-world conditions, where medical data are frequently collected inconsistently and are often incomplete; and the inherent difficulty of integrating heterogeneous data modalities. In this work, we introduce a newly curated multi-center, multi-modal, and longitudinal dataset designed to support the evaluation of a wide range of learning pipelines under realistic conditions. The dataset comprises a total of 1,365 lung cancer patients and has three imaging modalities (whole-slide images, CT scans, and PET scans), structured clinical data, transcriptomic, and longitudinal follow-up and treatment information. For each imaging modality the dataset contains more than one instance. Moreover, the dataset exhibits substantial and non-uniform missingness across modalities, making it well-suited for studying robust multi-modal fusion strategies. We further provide both uni-modal and multi-modal benchmarks on the task of 12-month overall survival prediction, disease-specific survival, as well as longitudinal benchmark of hazard prediction under severe missing data. Our results show that, despite high levels of missingness, integrating complementary modalities consistently improves predictive performance over uni-modal approaches, highlighting the value of multi-modal fusion in realistic clinical settings. The dataset and benchmark code are available at https://github.com/ritacmendes/MMIST-LUNG.

0.33

Glyph: An Interpretability Engine for AI-Driven Scientific Discovery in Clinical Data

cs.AI ·2026-11-06 ·Robbie Holland, Ashwin Kumar, Mateus A. Esmeraldo, David Le, Andrea Fisher +17 more
code/data similarity 0.66
Abstract

Automated scientific discovery has the potential to advance understanding of disease mechanisms and accelerate identification of early disease markers. Manual data annotation is infeasible at population scale, motivating methods that automatically extract pre-defined phenotypes in multimodal and unstructured clinical data. Such pre-defined feature sets determine and limit which associations these approaches can discover. This limitation extends to agentic AI systems that use these tools to query population-scale data. In contrast, foundation models (FMs) trained on large volumes of clinical data can perform tasks beyond their training objectives. This suggests their latent embeddings may represent novel or unexplored features that could yield insights into disease mechanisms, yet such latent features remain difficult to interpret. To address this challenge, we introduce Glyph, an automated multistage framework that extracts features from multimodal and unstructured clinical data using FMs and sparse autoencoders, interprets them as coded clinical concepts, and evaluates their value for clinical scientific discovery. We applied Glyph to abdominal CT volumes, CT radiology reports and laboratory measurements from 41,628 patients across different institutions. We identified 397 predictive concepts supported by 4,463 Bonferroni-significant associations. Moreover, a majority of discovered associations were automatically reproducible in held-out cohorts across different sites. Glyph concepts provided complementary associations to literature-derived markers, leading to gains in predictive power. We envision that interpretability can extend beyond a mechanistic understanding of neural networks to connecting implicitly learned features with clinical knowledge and establishing their significance for patient outcomes. We release Glyph at https://github.com/StanfordMIMI/Glyph.

0.40

Mol-JEPA: A multimodal Joint Embedding Predictive Architecture for Molecules

cs.LG cs.AI ·2026-08-23 ·Florian Rottach, Sebastian Schieferdecker, William Rudman, Randall Balestriero, Carsten Eickhoff
similarity 0.66
Abstract

Despite recent advances in molecular foundation models, several limitations remain, such as chemically invalid augmentations, modality collapse, and incomplete representation of biochemical environments. To address these challenges, we present \textbf{Mol-JEPA}, a scalable framework for learning molecular world models. Rather than relying on suboptimal molecular perturbations, our model uses modality masking to exploit information from molecular structures, cellular phenotypes, binding affinities, ADMET profiles, quantum chemistry simulations and other drug discovery data. Across various benchmarks, we show that the representations learned by Mol-JEPA deliver strong performance, demonstrating the value of incorporating biochemical context through latent space prediction.

0.28

ScreenShot: A Foundation Model for Few-Shot Combination Drug Screening

cs.LG ·2026-08-12 ·Antoine de Mathelin, Christopher Tosh, Wesley Tansey
code/data similarity 0.65
Abstract

Treating patients with combinations of drugs reduces the risk of resistance to any individual drug. Finding effective combinations is difficult because the large search space makes combinatorial screens prohibitively expensive, time consuming, and often technically infeasible. Predictive models can fill this gap, yet existing methods typically require molecular profiling of each sample and per-cohort training, limiting their applicability when time and tissue are scarce. To address this challenge, we introduce ScreenShot, a hierarchical transformer pretrained on 40 drug screening datasets covering 3,700 drugs and 6,000 biological samples, whose architecture mirrors the nested structure of screening data. Given a few-shot context of observations from a new patient, ScreenShot predicts the response of the sample to combination therapies through in-context learning, operating directly on functional measurements with no fine-tuning and no molecular profiling. On four held-out datasets, ScreenShot outperforms all baselines in both prediction accuracy and identification of selectively effective treatments. ScreenShot's internal representations are directly useful for experimental design: we use them to drive a weighted k-means++ active learning strategy that selects which experiments to run, achieving the same hit detection as uniform screening with a third of the budget. Source code and interactive dashboard: https://github.com/tansey-lab/screenshot.

0.24

A Multimodal Foundation Model for Longitudinal Patient Representation and Scalable Insight Generation in Oncology

cs.LG ·2026-08-25 ·Eugene Vorontsov, Yi Kan Wang, Alican Bozkurt, Adam Casson, Ludmila Tydlitatova +11 more
similarity 0.65
Abstract

Precision oncology necessitates a longitudinal model of patient state that captures cancer evolution and treatment over time, integrating multimodal observations. We introduce the oFM, a foundation model developed on a real-world oncology cohort of 1.67 million cancer patients that integrates clinical trajectories with DNA, RNA, and H&E pathology. Patient-level partitions were reserved for training, validation, and testing, with over one million patients used for training. The oFM encodes daily clinical and molecular episodes and, along with pathology images, integrates them over time to produce a patient state embedding. We evaluate frozen oFM embeddings against expert-curated clinical and molecular baseline features. In prognostic benchmarks, the oFM improved AUC for treatment response, progression-free survival, and overall survival (0.774 vs. 0.563 for overall survival). Across 11 comparative-treatment cohorts, the oFM embeddings achieved a three-fold higher pooled and scale-normalized treatment-benefit AUTOC than baseline features with improved benefit ranking in 9 of 11 cohorts, and provided stronger prognostic discrimination within both treatment arms. We also evaluated a mechanism discovery framework that interprets downstream models built on oFM embeddings by linking their predicted outcomes to clinically and biologically grounded mechanisms through an evidence-grounded temporal graph, enabling evaluation in clinical and drug-development applications.

0.09

Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

cs.LG q-bio.QM ·2026-08-11 ·Vincent Lavelle, Yitan Zhu, Kaitlyn Marlor, Thomas Brettin, Rick Stevens
benchmarkdataset similarity 0.65
Abstract

Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.

0.04